SYCP2L — The Meiotic Scaffold Protein That Governs Your Ovarian Clock
Inside every primary oocyte, a protein called SYCP2L quietly anchors chromosomes to their meiotic pairing sites. When the synaptonemal complex assembles during prophase I — the critical period when maternal and paternal chromosomes zip together and exchange genetic material — SYCP2L acts as a structural anchor, localising specifically to oocyte centromeres. Without it, chromosomes pair imperfectly, recombination fails, and eggs accumulate meiotic errors that ultimately deplete the ovarian reserve faster than normal.
rs9348724 sits 2 kilobases upstream of SYCP2L, in a regulatory region that influences the gene's expression. The minor C allele at this position is associated with a later age at natural menopause — roughly 0.26 additional years per C copy. Because the GG genotype is the global majority (carried by about 65% of European women), most people experience average menopause timing; those with one or two copies of the C allele tend to retain functional ovarian reserve somewhat longer.
The Mechanism
SYCP2L is a paralogue of synaptonemal complex protein 211 paralogue of synaptonemal complex protein 2
SYCP2 — the canonical
lateral element component that
is expressed exclusively in oocytes and localises to primordial follicle centromeres.
In SYCP2L-knockout female mice, primordial oocyte pools deplete progressively with
age at a rate significantly faster than wild-type controls, and fertility declines
earlier. The defect traces to impaired centromere fidelity during meiotic prophase,
leading to spindle misalignment and downstream chromosome segregation errors.
The rs9348724 locus is a regulatory variant, not a coding change, so its effect operates through altered SYCP2L expression levels rather than a structural protein change. The C allele is hypothesised to support slightly higher or more sustained SYCP2L expression, maintaining centromere integrity over a longer reproductive lifespan. At the severe end, homozygous loss-of-function mutations in SYCP2L cause premature ovarian insufficiency (POI) — amenorrhoea with elevated FSH before age 40 — demonstrating that full SYCP2L function is necessary for normal ovarian longevity.
The Evidence
The primary association comes from Ruth et al. 202122 Ruth et al. 2021
Genetic insights into biological
mechanisms governing human ovarian ageing. Nature 596:393–397,
the largest menopause GWAS to date (201,323 women). rs9348724 reached genome-wide
significance at p = 4×10⁻¹¹² with a beta of +0.255 years per C allele — one of the
strongest single-variant effects in the study. The paper implicates the broader
meiotic DNA damage response and synaptonemal complex assembly pathway as a key
determinant of ovarian ageing pace.
The functional story was established by Zhou et al. 201533 Zhou et al. 2015
Accelerated reproductive
aging in females lacking a novel centromere protein SYCP2L. Hum Mol Genet,
who showed that SYCP2L-knockout mice lose primordial oocytes at an accelerated
rate and have reduced litter sizes. In humans, the intronic rs2153157 splice
variant at the same locus changes U12-type minor intron splicing efficiency, with
the more-efficiently-spliced allele associating with delayed menopause. Together,
these findings converge on the conclusion that SYCP2L dose matters for reproductive
lifespan.
At the clinical extreme, He et al. 202144 He et al. 2021
J Med Genet
identified homozygous loss-of-function SYCP2L mutations in POI patients, confirming
the gene as a bona fide cause of ovarian failure. Rosa et al. 202355 Rosa et al. 2023
JBRA Assist
Reprod further showed that SYCP2L
rs2153157 AA genotype correlates with significantly lower anti-Müllerian hormone
(AMH) levels (p=0.01), a direct biomarker of ovarian reserve, in IVF patients.
Practical Actions
For women carrying two copies of the common G allele (GG), there is no specific intervention required — ovarian reserve follows the population-average trajectory. Monitoring AMH and antral follicle count before age 35 can establish a personal baseline, particularly if family history suggests early menopause.
Coenzyme Q10 has the strongest evidence for supporting oocyte mitochondrial quality during the meiotic process. Ben-Meir et al. 201566 Ben-Meir et al. 2015 demonstrated that age-related oocyte quality decline — driven by reduced CoQ10 biosynthesis and impaired mitochondrial ATP production — is reversible with CoQ10 supplementation in mouse models, with reduced spindle misalignment in treated animals. In a human RCT, Xu et al. 201877 Xu et al. 2018 showed that 60 days of CoQ10 pretreatment improved oocyte retrieval numbers, fertilisation rates, and embryo quality in women with poor ovarian reserve. A 2024 meta-analysis of 20 RCTs identified 30 mg/day for 3 months prior to stimulation as the optimal protocol for improving pregnancy rates.
Interactions
The strongest interaction at this locus is with rs2153157, another SYCP2L variant (intronic, affecting splice efficiency) that independently associates with menopause timing. Both rs9348724 and rs2153157 are within the same gene and likely act through shared expression regulation, but they are not in complete LD — a user carrying the beneficial allele at one position may or may not carry it at the other.
Downstream pathway interactions are worth noting: impaired synaptonemal complex assembly sensitises oocytes to DNA double-strand break accumulation. Variants in DNA repair genes (e.g. MCM8, BRCA2 pathway components) that also associate with menopause timing in the Ruth 2021 GWAS may compound effects on oocyte longevity.